{"id":"xibrom-and-pred-forte","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Increased intraocular pressure (with corticosteroid)"},{"rate":null,"effect":"Corneal erosion or delayed healing"}]},"_chembl":{"chemblId":"CHEMBL537","moleculeType":"Small molecule","molecularWeight":"110.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromfenac works by inhibiting COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis and decreasing ocular inflammation. Prednisolone acetate is a topical corticosteroid that binds to glucocorticoid receptors to suppress inflammatory cytokine production and immune cell activation. Together, these agents provide complementary anti-inflammatory effects for post-operative ocular inflammation.","oneSentence":"Xibrom (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, while Pred Forte (prednisolone acetate) is a corticosteroid that suppresses immune and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:26.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-operative inflammation and pain following cataract surgery"},{"name":"Ocular inflammation associated with ophthalmic surgery"}]},"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT01193504","phase":"PHASE4","title":"Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification","status":"UNKNOWN","sponsor":"Innovative Medical","startDate":"2010-09","conditions":"Pseudophakia, Cataract Surgery","enrollment":100},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":"Cataracts","enrollment":49},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200},{"nctId":"NCT00469781","phase":"PHASE4","title":"Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening","status":"COMPLETED","sponsor":"Center For Excellence In Eye Care","startDate":"2007-05","conditions":"Cystoid Macular Edema,, Retinal Thickening","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xibrom and Pred Forte","genericName":"Xibrom and Pred Forte","companyName":"Bp Consulting, Inc","companyId":"bp-consulting-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xibrom (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, while Pred Forte (prednisolone acetate) is a corticosteroid that suppresses immune and inflammatory responses. Used for Post-operative inflammation and pain following cataract surgery, Ocular inflammation associated with ophthalmic surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}